Wedbush reaffirmed their outperform rating on shares of Nightstar Therapeutics (NASDAQ:NITE) in a research note published on Wednesday morning, MarketBeat.com reports. They currently have a $31.00 price target on the stock, up from their previous price target of $29.00. Wedbush also issued estimates for Nightstar Therapeutics’ FY2021 earnings at ($1.18) EPS and FY2022 earnings at $1.02 EPS.

NITE has been the topic of several other research reports. Jefferies Group initiated coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They set a buy rating and a $25.00 price objective on the stock. Chardan Capital initiated coverage on shares of Nightstar Therapeutics in a report on Wednesday, January 3rd. They set a buy rating and a $40.00 price objective on the stock. Leerink Swann initiated coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They set an outperform rating and a $25.00 price objective on the stock. Finally, BMO Capital Markets initiated coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They set an outperform rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a buy rating, Nightstar Therapeutics has an average rating of Buy and a consensus price target of $30.20.

Nightstar Therapeutics (NASDAQ:NITE) traded up $0.52 during trading hours on Wednesday, hitting $14.73. 9,520 shares of the stock traded hands, compared to its average volume of 31,754. Nightstar Therapeutics has a one year low of $11.99 and a one year high of $24.93. The company has a market cap of $404.09 and a P/E ratio of -29.46.

A number of hedge funds and other institutional investors have recently bought and sold shares of NITE. Citadel Advisors LLC bought a new stake in Nightstar Therapeutics in the third quarter valued at about $240,000. Nationwide Fund Advisors bought a new stake in Nightstar Therapeutics in the third quarter valued at about $1,196,000. Sphera Funds Management LTD. bought a new stake in Nightstar Therapeutics in the third quarter valued at about $1,728,000. Alyeska Investment Group L.P. bought a new stake in Nightstar Therapeutics in the third quarter valued at about $1,920,000. Finally, Chartwell Investment Partners LLC bought a new stake in Nightstar Therapeutics in the third quarter valued at about $3,995,000. 27.12% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2018/01/21/nightstar-therapeutics-nite-stock-rating-reaffirmed-by-wedbush.html.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.